12 October 2021
This was a public lecture, the first of the UCL Faculty of Medical Sciences lecture series, 2021.
It is also available on the UCL FMS YouTube channel at [ Ссылка ]
Improving breast cancer treatment: Long-term results of the TARGIT-A randomised trial (www.targit.org.uk) of risk-adapted single-dose TARGIT-IORT given during lumpectomy for breast cancer vs whole breast radiotherapy given post-operatively by visiting the radiotherapy centre daily for 3 to 6 weeks.
Selected recent scientific papers and talks
1) The BMJ paper is available at [ Ссылка ]
The accompanying opinion piece is at [ Ссылка ]
UCL video is at [ Ссылка ]
BMJ academic video is at [ Ссылка ]
2) Further analysis paper published in the British Journal of Cancer can be accessed at [ Ссылка ]
and an invited blog post about it is here [ Ссылка ]
and a short video is at [ Ссылка ]
3) Comparison of 'no-radiotherapy' trials, compressed whole breast radiotherapy trials and other partial breast irradiation randomised trial is published in Nature Reviews Clinical Oncology at [ Ссылка ] as part of the article [ Ссылка ]
and in the British Journal of Cancer [ Ссылка ]
4) Worldwide adoption is described in this UCL Discovery preprint
[ Ссылка ]
5) How TARGIT-IORT is very different from ELIOT
[ Ссылка ]00278-3/fulltext
6) How TARGIT-IORT is better for patients than other Partial Breast Irradiation (PBI) approaches
[ Ссылка ]00199-1/fulltext
Slide credit - Jayant S Vaidya and Uma J Vaidya
